{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T22:32:17Z","timestamp":1768602737276,"version":"3.49.0"},"reference-count":74,"publisher":"Informa UK Limited","issue":"11-12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Grant Agency of Charles University"},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["SVV 260 784"],"award-info":[{"award-number":["SVV 260 784"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/17425255.2025.2595661","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:56:03Z","timestamp":1764194163000},"page":"1315-1326","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Tirabrutinib\u2013anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance"],"prefix":"10.1080","volume":"21","author":[{"given":"Lucie","family":"\u010cerm\u00e1kov\u00e1","sequence":"first","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Novotn\u00e1","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"La\u0161tovi\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Chmurov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdal\u00e9na","family":"Ka\u0161parov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Lebekov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivona","family":"\u0160pringrov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Macone","sequence":"additional","affiliation":[{"name":"Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bonamore","sequence":"additional","affiliation":[{"name":"Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Ws\u00f3l","sequence":"additional","affiliation":[{"name":"Charles University","place":["Hradec Kralove, Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu050"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219747110"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7164"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050305"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197611)38:5<1909::AID-CNCR2820380507>3.0.CO;2-Q"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01842886"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00082-B"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118699"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02401-6"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200211150-00014"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520615666150407155319"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113052"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114415"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/088800199277452"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00322-6"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.206805"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.173179"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2014.04.027"},{"issue":"8","key":"e_1_3_6_20_1","first-page":"743","article-title":"Differential expression of type 2 3alpha\/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system","volume":"3","author":"Park AL","year":"2010","unstructured":"Park AL, Lin HK, Yang Q, et al. Differential expression of type 2 3alpha\/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol. 2010;3(8):743\u2013754.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2010.11.004"},{"issue":"2","key":"e_1_3_6_22_1","first-page":"505","article-title":"The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs","volume":"63","author":"Desmond JC","year":"2003","unstructured":"Desmond JC, Mountford JC, Drayson MT, et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 2003;63(2):505\u2013512.","journal-title":"Cancer Res"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000206"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603288"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050964"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad008"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-025-00889-4"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0600-7"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282166"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2008.10.015"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-13-RG-051"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.08.001"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.02.035"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0ib00130a"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018895"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024711"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.05.005"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00124-I"},{"key":"e_1_3_6_41_1","unstructured":"Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley-Interscience; 2005."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118540398"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1040990107"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.10526"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00311.2009"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2007.06.005"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-232"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2007.06.017"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797440186"},{"issue":"9","key":"e_1_3_6_50_1","first-page":"2066","article-title":"Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue","volume":"56","author":"Forssen EA","year":"1996","unstructured":"Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 1996;56(9):2066\u20132075.","journal-title":"Cancer Res"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00648-z"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015735815111"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004010050756"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910580619"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063116"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-254"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.07.017"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-50"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01318-8"},{"key":"e_1_3_6_60_1","unstructured":"Ono Pharmaceutical Co. L. Ono receives a supplemental approval in Japan for Velexbru tablet 80mg a BTK inhibitor for additional indication of Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. News release. Ono Pharmaceutical Co Ltd. 2020. [cited 2025 Jul 27]. Available from: https:\/\/www.ono-pharma.com\/sites\/default\/files\/en\/news\/press\/sm_cn200821_1.pdf"},{"key":"e_1_3_6_61_1","unstructured":"Ono Pharmaceutical Co. L. Ono receives a manufacturing and marketing approval for Velexbru\u00ae tablet 80mg a BTK inhibitor for treatment of recurrent or refractory primary central nervous system lymphoma in Japan. News release. Ono Pharmaceutical Co. Ltd. 2020 [cited 2025 Jul 27]. Available from: https:\/\/www.ono-pharma.com\/sites\/default\/files\/en\/news\/press\/sm_cn200325.pdf"},{"key":"e_1_3_6_62_1","unstructured":"Ono Pharmaceutical Co. L. ONO Pharmaceutical Co. Ltd. Velexbru\u00ae tablet 80 mg a BTK inhibitor approved in South Korea for treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Press release. 2021. [cited 2025 Jul 27]. Available from: https:\/\/www.ono-pharma.com\/sites\/default\/files\/en\/news\/press\/enews_Velexbru%20PCNSL%20approved%20in%20South%20Korea_20211108.pdf"},{"key":"e_1_3_6_63_1","unstructured":"Ono Pharmaceutical Co. L. Velexbru\u00ae tablet 80 mg a BTK inhibitor approved in Taiwan for the treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Press release. 2022. [cited 2025 Jul 27]. Available from: https:\/\/www.ono-pharma.com\/sites\/default\/files\/en\/news\/press\/enews_Velexbru%20PCNSL%20approved%20in%20Taiwan_20220221.pdf"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134546"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1138292"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.012"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01763-6"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13983"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae037"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02138"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1378292"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000122"},{"issue":"7","key":"e_1_3_6_73_1","first-page":"3645","article-title":"A novel selective AKR1C3-activated prodrug AST-3424\/OBI-3424 exhibits broad anti-tumor activity","volume":"11","author":"Meng F","year":"2021","unstructured":"Meng F, Li WF, Jung D, et al. A novel selective AKR1C3-activated prodrug AST-3424\/OBI-3424 exhibits broad anti-tumor activity. Am J Cancer Res. 2021;11(7):3645\u20133659.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2008.12.010"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2009.12.009"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2595661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:17:19Z","timestamp":1768562239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2595661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":74,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/17425255.2025.2595661"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2595661","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}